Article
Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.
Scientific reports - 20 Feb 2026
Florou-Chatzigiannidou Chrysiida, Papadopoulou Eirini, Metaxa-Mariatou Vasiliki, Tsantikidi Aikaterini, Maxouri Stella, Tsaousis Georgios, Grigoriadis Dimitris, Touroutoglou Nikolaos, Ziogas Dimitrios, Zairi Eleni, Alevizopoulos Nektarios, Corneliu Jinga Dan, Polixenia Iorga, Ozdogan Mustafa, Bilir Cemil, Hacibekiroglu Ilhan, Lacin Sahin, Ajami Ramin, El Hachem Georges, Nasioulas George, Bramis Konstantinos, Konstadoulakis Manousos, Papadimitriou Christos
Abstract excerpt
The application of advanced next-generation sequencing (NGS) technologies in the analysis of circulating tumor DNA (ctDNA) enabled the comprehensive evaluation of tumor-derived alterations in the bloodstream. In this study, we evaluated the analytical performance and clinical utility of a large-scale liquid biopsy assay in patients with metastatic cancer. A total of 1,110 unique patients underwent ctDNA NGS...
Topics
Join the communities discussing this publication.
